Cyclin degradation for cancer therapy and chemoprevention.

Cyclin degradation for cancer therapy and chemoprevention. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cyclin degradation for cancer therapy and chemoprevention. Abstract Text:

Sarah J Freemantle,Xi Liu,Qing Feng,Fabrizio Galimberti,Steven Blumen,David Sekula,Sutisak Kitareewan,Konstantin H Dragnev,Ethan Dmitrovsky,

Cancer is characterized by uncontrolled cell division resulting from multiple mutagenic events. Cancer chemoprevention strategies aim to inhibit or reverse these events using natural or synthetic pharmacologic agents. Ideally, this restores normal growth control mechanisms. Diverse classes of compounds have been identified with chemopreventive activity. What unites many of them is an ability to inhibit the cell cycle by specifically modulating key components. This delays division long enough for cells to respond to mutagenic damage. In some cases, damage is repaired and in others cellular damage is sufficient to trigger apoptosis. It is now known that pathways responsible for targeting G1 cyclins for proteasomal degradation can be engaged pharmacologically. Emergence of induced cyclin degradation as a target for cancer therapy and chemoprevention in pre-clinical models is discussed in this article. Evidence for cyclin D1 as a molecular pharmacologic target and biological marker for clinical response is based on experience of proof of principle trials.

Cyclin degradation for cancer therapy and chemoprevention. Publishing Authors By Initials

SJ Freemantle,X Liu,Q Feng,F Galimberti,S Blumen,D Sekula,S Kitareewan,KH Dragnev,E Dmitrovsky,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Cyclin degradation for cancer therapy and chemoprevention. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of cellular biochemistry

VOLUME: 102

Page Numbers: 869-77

Journal Abbreviation: J. Cell. Biochem.

ISSN: 0730-2312

DAY: 1

MONTH: Nov

YEAR: 2007

Cyclin degradation for cancer therapy and chemoprevention. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8205768

Cyclin degradation for cancer therapy and chemoprevention. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Cyclin degradation for cancer therapy and chemoprevention. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Cyclin degradation for cancer therapy and chemoprevention.

AFFILIATION: Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, New Hampshire 03755, USA. sarah.freemantle@dartmouth.edu

Country: United States

AGENCY: United States NCI

GRANT: T32 CA009658

ACRONYM: CA

MEDLINETA: J Cell Biochem

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cyclin degradation for cancer therapy and chemoprevention Related Publications

• A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis.
• Cyclin degradation for cancer therapy and chemoprevention.
• G0S2 is an all-trans-retinoic acid target gene.
• Gene profiling uncovers retinoid target genes.
• Growth factors in human germ cell cancer.
• Involvement of UBE1L in ISG15 conjugation during retinoid-induced differentiation of acute promyelocytic leukemia.
• Lysosomes and trivalent arsenic treatment in acute promyelocytic leukemia.
• Repression of cyclin D1 as a target for germ cell tumors.
• Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas.
• UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation.
• Uncovering novel targets for cancer chemoprevention.
• Uncovering residues that regulate cyclin D1 proteasomal degradation.